Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Its time to buy for me when it went under 112. 111.91. Good for a 3 point pop tomorrow before the bell. IMO
BMY will pursue a "Merger" with Celgene CELG as soon as Friday May 1. There will be a premium offered to CELG for Merger of Equals
Celgene Revlimid approved by EC
Celgene International Sàrl, a wholly owned subsidiary of Celgene, announced that the European Commission, or EC, has approved Revlimid for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant. The Revlimid Marketing Authorisation has been updated to include this new indication in multiple myeloma, building upon the already approved indication of Revlimid in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. Multiple myeloma is a persistent and life-threatening blood cancer that is characterised by tumour proliferation and suppression of the immune system. It is a rare but deadly disease: around 38,900 people were newly diagnosed with multiple myeloma in Europe in 2012, and 24,300 people died from the disease in the same year. On average, multiple myeloma is diagnosed in people 65-74 years of age, and the majority of newly diagnosed patients may not be eligible for more aggressive treatment options such as high-dose chemotherapy with stem cell transplant. The EC decision in newly diagnosed multiple myeloma was based on the results of two pivotal studies: MM-020 and MM-015
Celg. It might go back to 120-121. That would be a time to exit. I got out Friday.
I hope not. Still holding out for some good news from the fda. I think the deadline is feb 22 for revlimid as a first line therapy for mm
Celg. Looks to have peaked. Need to look for another.
I heard that some hedge fund manager is fighting against a few companies patents. Accordia and celgene.
CELG: I have never been a holder of CELG shares, long or short. But it has been on my watch list, and it has been a major holding of a Fidelity Select fund, FBIOX, in which I am invested. Like many of the previous posters, antecedent to this post, I thus have had more than idle concern as to the reason for a steady decline in share price the past few days.
1) You may want to check the SEC filings in the past week or so to see what institutional investors, if any, have been disposing of shares, presumably taking profits.
Look particularly for hedge funds--their profit taking may or may not be accompanied immediately thereafter by a short sale to gain additional profit on the decline in share price following any concerted effort by many of them to take STCG or LTCG profits.
2)I posted the following on the JNJ board yesterday[JNJ also has undergone a steady decline in share price in the past few days].
""NEW BRUNSWICK, N.J., Feb. 12, 2015 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced receipt of a further action from the Patent and Trademark Office regarding the re-examination of U.S. Patent No. 6,284,471 ('471) relating to REMICADE® issuing a final rejection of the patent.
We have sixty days to respond to this action and will do so. Currently the '471 patent expires in September 2018. We believe the '471 patent is valid and, if necessary, will pursue all available appeals."
I currently do not know whether the reexamination request was initiated 1) by one or more hedge funds wishing to short or profit on any decline in the share price in JNJ stock,2) by one or more generic drug companies wishing to attempt to enter the market earlier than the patent expiration date in 2018, or 3) by JNJ itself.
Meg Tirrell on CNBC reported today[5:30-5:45 pm] that other companies' patents may be under similar attacks where the product involved accounts for a substantial portion of the company's revenue, e.g. BIIB and CELG[REVLIMID].
The patent involving Remicade, Meg said earlier, protects $7 billion in JNJ revenue."
I suggest a check of PTO records to determine whether CELG's REVLIMID patent is undergoing reexamination; if it is, see who instigated/requested/petitioned for that re-exam and the results of any such proceeding to date. CELG itself may have issued a PR regarding any extant reexamination of its REVLIMID patent(s).
I do not know whether you holders of CELG shares will be able to draw definitive conclusions from any investigation pursuant to 1) or 2) above.
Oh ok. I hope we get some good news soon. An fda approval would be nice
Maybe. Also some tweets about a downgrade or cautious outlook by a boutique firm coming.
Isn't the fda making a decision on revlimid as first line therapy soon?
No idea. Nothing really trending. I guess they had a conference yesterday. Not sure if that was good or bad
Good time to buy or get out?
Was just looking to see. Broke the 50 day which it hasn't done in a long time.
Celgene announces positive recommendation by SMC for ABRAXANE, gemcitabine combo
Celgene International Sarl, a wholly owned subsidiary of Celgene, announced that ABRAXANE, in combination with gemcitabine, has now received a positive recommendation for the treatment of metastatic pancreatic cancer by the Scottish Medicines Consortium, or SMC, within the National Health Service Scotland. The decision follows the recent NHS England announcement to defer their review of ABRAXANE for metastatic pancreatic cancer, allowing the treatment to remain on the National Cancer Drugs Fund, or NCDF, list until a final decision is made. The mortality of pancreatic cancer is high, making it the fourth deadliest cancer for both men and women across the European Union. Patients diagnosed with metastatic disease have a median life expectancy, after diagnosis, of approximately two to six months. In the UK, pancreatic cancer is the fifth most common cancer killer with approximately 8,800 new cases diagnosed each year. In Scotland an estimated 770 new patients are diagnosed and over 740 die from the disease each year.
CEO Bob Hugin is on CNBC now....solid interview!
Market is closed on Monday due to a holiday.
In Reply to 'Bio-Invest'
There is no fundamental reason for the Market to go down- CELG has low volume today, only weak retail investors selling.
CELG is far to be oversold, we are at 70% under the resistance line of the main uptrend channel, started Oct 15, 2014, and the RSI is at 58.
It is time to buy, we should see green next Monday and next week.
There is no fundamental reason for the Market to go down- CELG has low volume today, only weak retail investors selling.
CELG is far to be oversold, we are at 70% under the resistance line of the main uptrend channel, started Oct 15, 2014, and the RSI is at 58.
It is time to buy, we should see green next Monday and next week.
Celgene price target raised to $142 from $109 at Bernstein
Bernstein hiked its price target on Celgene after the company preannounced higher than expected EPS and in-line revenue. The firm increased its price target based on increasing multiples for higher growth large cap healthcare companies. Bernstein believes that the company expects to exceed its 2015 guidance, and the firm keeps an Outperform rating on Celgene
I think the interesting thing this chart shows is the price action around the 50day MA. Outside of the 3 day market meltdown in October this stock hasn't breached the 50 to the downside and infect bounces hard of it when it hits it... just as it has started to today after yesterday sector pull back.
The PPS separation from 250MA means little in my opinion. You're also pointing to 119 and the green line. This isn't trading at 119 and therefore the spread you're pointing out doesn't exist. Yesterday's pull back had nothing to do with the deviation from the 250 and everything to do with GILD causing the whole sector pull back. If the deviation from 250 was the catalyst then it would've appeared in EVERY pharma chart the past few days.
Charts are interesting, but they aren't telling the whole story this week in biotech
The SEC should ban the show for false information and using the show for his own personal gain.
Cramer is bashing biotechs while he loads up!
LOL
Celgene and Nuvilex: I believe they may already be in communication and planning on how Together they might bring Cell-In-The-Box to Market and Patient sooner rather than later. FDA ODD Designation for $NVLX on Friday at Noon: Shot Up > 15% without a PR Announcement Yet. Tomorrow might just Be The Day Nuvilex makes itself known to The World.......
Nuvilex just got FDA ODD approved
Maybe a buy-out with Celgene Corporation since they are similar
http://www.accessdata.fda.gov/scripts/opdlisting/oopd/oopd_results_2.cfm?index_number=457014
Celgene Receives Positive CHMP Opinion to Extend REVLIMID® (Lenalidomide) for Continuous Use in Patients with Newly Diagnose...
Source: Business Wire
Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for continuous oral treatment with REVLIMID® in adult patients with previously untreated multiple myeloma who are not eligible for stem cell transplantation.
The CHMP reviews applications for all 28 member states in the European Union (EU), as well as Norway, Liechtenstein and Iceland. The European Commission, which generally follows the recommendation of the CHMP, is expected to make its final decision in approximately two months. If approval is granted, detailed conditions for the use of this product will be described in the Summary of Product Characteristics (SmPC), which will be published in the revised European Public Assessment Report (EPAR).
Multiple myeloma is a persistent and life-threatening blood cancer that is characterised by tumour proliferation and suppression of the immune system. 1 It is a rare but deadly disease: around 38,900 people were newly diagnosed with multiple myeloma in Europe in 2012, and 24,300 people died from the disease in the same year. 2 On average, multiple myeloma is diagnosed between 65-74 years of age. 3 The majority of newly diagnosed patients are not eligible for more aggressive treatment options such as high-dose chemotherapy with stem cell transplant,4 and there is currently no therapy option approved for continuous treatment to help manage the disease over the long term. 5
“When recommending a therapy at first diagnosis, our aim is to keep the disease under control for as long as possible,” says Professor Thierry Facon, Services des Maladies du Sang, Hôpital Claude Huriez, and CHRU Lille, France. “The positive opinion for REVLIMID for the continuous treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant is a significant step towards bringing a new therapy that could extend the time patients live without their disease progressing.”
The anticipated European Commission decision would be the latest milestone for Celgene’s flagship product in Europe and its continued focus on delivering innovative medicines for rare haematological diseases. REVLIMID is already indicated in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. REVLIMID is also indicated for the treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.
Tuomo Pätsi, President of Celgene in Europe, the Middle East and Africa (EMEA), said, “The CHMP opinion reflects the important role that therapies like REVLIMID play in treating rare haematological cancers including multiple myeloma. Innovative medicines have been critical in helping to improve patient outcomes, but despite tremendous progress over the last 10 years, myeloma remains incurable for the vast majority of patients, so new treatments are needed. At Celgene, we will continue to invest more than one-third of our revenues back into research and development to continue finding new treatment options for these patients. Our hope is that one day, deadly diseases like multiple myeloma could become a manageable, long-term chronic condition.”
The CHMP recommendation in newly diagnosed multiple myeloma was based on the results of two pivotal studies: MM-015 and MM-020 (also known as FIRST). The results of these studies have been reported previously.
The FIRST study, MM-020,6 was the largest phase III, randomised study of 1,623 patients newly diagnosed with multiple myeloma and not eligible for stem cell transplantation. It compared lenalidomide–dexamethasone (Rd) administered in 28-day cycles until disease progression, with Rd for 72 weeks (18 cycles), and melphalan–prednisone–thalidomide (MPT) for 72 weeks.
MM-0157 was a phase III study of 459 patients that compared melphalan–prednisone–lenalidomide induction followed by lenalidomide maintenance (MPR-R) with melphalan–prednisone–lenalidomide (MPR) or melphalan–prednisone (MP) followed by placebo in patients =65 years or older with newly diagnosed multiple myeloma.
Yep!!! NP! Rock n Roll!
Seeing some progress against disease is always a good thing. ;)
Thanks for posting.
In Reply to 'jimmybob'
$CELG : Celgene reports Vidaza Phase III study shows doubled overall survival times
Celgene announced that data from two sub-group analyses from AML-001, its phase III study of Vidaza compared with conventional care regimens, or CCR, in elderly subjects with newly diagnosed acute myeloid leukemia, were presented at the 56th American Society of Hematology annual meeting.
In this global, multi-center, randomized, open-label pivotal study, patients at least 65 years old with newly diagnosed or secondary AML with greater than 30% bone marrow blasts were pre-selected to receive one of three regimens per investigator’s choice: intensive chemotherapy, low-dose Ara-C or best supportive care, or BSC, only.
Patients were then randomized to receive either azacitidine or their predetermined CCR. The sub-analyses were not powered to detect statistically significant differences.
In the first sub-analysis, Prof. Hervé Dombret reported results from the study focused on patients with AML with morphologic dysplastic changes, or AML-MDC. Of 488 patients in the AML-001 study, 158 had AML-MDC. In these patients, the median overall survival, or OS, was twice as long in patients who received azacitidine compared with those who received CCR. The one-year survival rate for patients receiving azacitidine was also higher compared with CCR.
Rates of patients achieving a complete remission plus morphological complete response with incomplete blood count were 26.7% with azacitidine compared with 19.3% with CCR.
For patients with AML-MDC who were pre-selected to receive LDAC before randomization to azacitidine or CCR, median OS was 13.2 months with azacitidine vs. 6.3 months in the LDAC group. The one-year survival rate with azacitidine was 55% vs. 31% with LDAC. Grade 3-4 adverse event rates included: anemia, neutropenia, febrile neutropenia and thrombocytopenia
$CELG : Celgene reports Vidaza Phase III study shows doubled overall survival times
Celgene announced that data from two sub-group analyses from AML-001, its phase III study of Vidaza compared with conventional care regimens, or CCR, in elderly subjects with newly diagnosed acute myeloid leukemia, were presented at the 56th American Society of Hematology annual meeting. In this global, multi-center, randomized, open-label pivotal study, patients at least 65 years old with newly diagnosed or secondary AML with greater than 30% bone marrow blasts were pre-selected to receive one of three regimens per investigator’s choice: intensive chemotherapy, low-dose Ara-C or best supportive care, or BSC, only. Patients were then randomized to receive either azacitidine or their predetermined CCR. The sub-analyses were not powered to detect statistically significant differences. In the first sub-analysis, Prof. Hervé Dombret reported results from the study focused on patients with AML with morphologic dysplastic changes, or AML-MDC. Of 488 patients in the AML-001 study, 158 had AML-MDC. In these patients, the median overall survival, or OS, was twice as long in patients who received azacitidine compared with those who received CCR. The one-year survival rate for patients receiving azacitidine was also higher compared with CCR. Rates of patients achieving a complete remission plus morphological complete response with incomplete blood count were 26.7% with azacitidine compared with 19.3% with CCR. For patients with AML-MDC who were pre-selected to receive LDAC before randomization to azacitidine or CCR, median OS was 13.2 months with azacitidine vs. 6.3 months in the LDAC group. The one-year survival rate with azacitidine was 55% vs. 31% with LDAC. Grade 3-4 adverse event rates included: anemia, neutropenia, febrile neutropenia and thrombocytopenia
That Forbes article doesn't exactly paint Soon-Shiong as someone who's word can be taken without proof.
Interesting post...thanks..
Found this interesting post on CELG:
60 minutes had this on last night,...
Here Is What '60 Minutes' Didn't Tell You About The Billionaire Who Is Trying To Disrupt Cancer Care
http://www.forbes.com/sites/matthewherper/2014/12/07/here-is-what-60-minutes-didnt-tell-you-about-the-billionaire-who-is-trying-to-disrupt-cancer-care/?partner=yahootix
AND
Soon-Shiong invented the first FDA approved nanoparticle delivery technology for the treatment of breast cancer, Abraxane, which is now approved in over 40 countries. The company he founded to develop and maufacture Abraxane, Abraxis Biosciences, was sold to Celgene for around $3 billion in 2010. Prior to that, Soon-Shiong founded and sold American Pharma Partners (APP) to Fresenius, a German dialysis company, for $5.6 billion, of which he got $3 billion. Now Soon-Shiong is looking to take his Midas touch and revolutionize healthcare with one of his NANTWORKS companies, NANTHEALTH.
Of the above companies, NANTOMICS, and NANTCLOUD are product offerings that fall under NANTHEALTH. NANTMEDIA and NANTBIOPHARMA seem to be operating in stealth mode with the latter taking in a $75 million investment from Celgene (NASDAQ:CELG) earlier this year. Nothing can be found yet for NANTMEDIA. NANTMOBILE is a technology company which is developing a mobile recognition technology platform. Of all these companies, it is NANTHEALTH that is emerging from stealth mode with some truly innovative products and solutions.
CELG looking solid today! coming off ASH presentation.
$CELG DD Notes ~ http://www.ddnotesmaker.com/CELG
bullish
$CELG recent news/filings
## source: finance.yahoo.com
Fri, 05 Dec 2014 11:45:00 GMT ~ Biotech stocks to watch at ASH
read full: http://finance.yahoo.com/video/biotech-stocks-watch-ash-114500645.html
*********************************************************
Fri, 05 Dec 2014 00:54:00 GMT ~ Can Health Care Sector's Fund Romp Continue?
[at Investor's Business Daily] - Of the three top-performing sector mutual fund categories of the past 15 years, health care has come a long way to catch the other two leaders: real estate and energy. A $10,000 investment in health care ...
read full: http://news.investors.com/120414-729245-can-health-care-fund-romp-continue.htm?ven=yahoocp&src=aurlled&ven=yahoo
*********************************************************
Tue, 02 Dec 2014 22:18:00 GMT ~ RBC's biotech picks: CELG, BMRN & VRTX
read full: http://finance.yahoo.com/video/rbc-39-biotech-picks-celg-221800969.html
*********************************************************
Tue, 02 Dec 2014 22:00:00 GMT ~ 7 Biotech stocks to buy now
read full: http://finance.yahoo.com/video/7-biotech-stocks-buy-now-220000627.html
*********************************************************
Tue, 02 Dec 2014 17:27:00 GMT ~ 4 Stocks, 4 trades: F, BIIB, PCLN & RCL
read full: http://finance.yahoo.com/video/4-stocks-4-trades-f-172700230.html
*********************************************************
$CELG charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$CELG company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/CELG/company-info
Ticker: $CELG
OTC Market Place: Not Available
CIK code: 0000816284
Company name: Celgene Corp.
Company website: http://www.celgene.com
Incorporated In: DE, USA
$CELG share structure
## source: otcmarkets.com
Market Value: $90,756,756,882 a/o Dec 04, 2014
Shares Outstanding: 798,704,188 a/o Oct 21, 2014
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.01
$CELG extra dd links
Company name: Celgene Corp.
Company website: http://www.celgene.com
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/CELG/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/CELG/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=CELG+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=CELG+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=CELG+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/CELG/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/CELG/news - http://finance.yahoo.com/q/h?s=CELG+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/CELG/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/CELG/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/CELG/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/CELG/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/CELG/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/CELG/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/CELG/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/CELG/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=CELG+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/CELG
DTCC (dtcc.com): http://search2.dtcc.com/?q=Celgene+Corp.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Celgene+Corp.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Celgene+Corp.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.celgene.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.celgene.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.celgene.com
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/CELG/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/CELG
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/CELG/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/CELG/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/CELG/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000816284&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/CELG/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/CELG/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/CELG/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/CELG/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=CELG&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=CELG
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/CELG/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=CELG+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=CELG+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=CELG
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=CELG
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=CELG+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/CELG/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=CELG+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/CELG.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=CELG
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/CELG/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/CELG/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/CELG/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/CELG/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/CELG
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/CELG
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/CELG:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=CELG
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=CELG
$CELG DD Notes ~ http://www.ddnotesmaker.com/CELG
CELGENE HAS A 15% STAKE IN AGIO CELGENE SHOULD BE TRADING AT LEASE $115-125 PLUS
It's been interesting watching it. I may look at calls in the morning. Have to do a bit of research on it anyway.
In Reply to 'DreamCha$er'
Stocks been getting beat down last 4 days...adding calls...hopefully pays off
Stocks been getting beat down last 4 days...adding calls...hopefully pays off
"All right, all right, all right!"
Kramer --Celgene a Monster of a stock a real Monster
On Mad Money On lightning round someone called in and he said Celgene a Monster of a stock a real Monster
Celg profit increased 37 % should of rally way over $150.000
NVLX TD2 / Dr. Daniel Von Hoff Pre-Clinical Study Results are due to be reported any time now. CELG might be very interested. Cell-In-The-Box is going to help the fight against both Cancer and Diabetes.
Followers
|
45
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
344
|
Created
|
01/23/06
|
Type
|
Free
|
Moderators |
Company Information:
Celgene Corp.
86 Morris Avenue
Summit, NJ 07901
Phone: (908) 673-9000
CIK
0000816284
Celgene Corporation, a publicly traded company…
Committed to Improving the Lives of Patients Worldwide
Celgene is a multinational biopharmaceutical company committed to improving the lives of patients worldwide.
At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our mission as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.
There are numerous clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocyte leukemia (CLL), non-Hodgkin's lymphoma (NHL), glioblastoma, and ovarian, pancreatic and prostate cancer.
As committed as we are to clinical accomplishment, we are equally committed to
Our portfolio of services and pharmaceutical products in the U.S. include: | ||
Products | ||
ALKERAN® (melphalan) tablets | ||
ALKERAN® (melphalan) for injection | ||
REVLIMID® (lenalidomide) | ||
THALOMID® (thalidomide) | ||
VIDAZA® (azacitidine for injection) | ||
Services | ||
LifebankUSA (placental and cord blood banking) |
Press Releases:
http://ir.celgene.com/phoenix.zhtml?c=111960&p=irol-news&nyo=0
Filings:
Transfer Agent:
American Stock Transfer & Trust Company
59 Maiden Lane
New York 10038
Last update 4.12.2010
All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
Rules of the board according to IHUB:
http://www.investorshub.com/boards/complex_terms.asp
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |